Cargando…

Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study

The rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mörck, Boel, Pullerits, Rille, Geijer, Mats, Bremell, Tomas, Forsblad-d'Elia, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780705/ https://www.ncbi.nlm.nih.gov/pubmed/24089587 http://dx.doi.org/10.1155/2013/289845

Ejemplares similares

Prevalence and factors related to sleep apnoea in ankylosing spondylitis
por: Wiginder, Adrian, et al.
Publicado: (2021)

Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment
por: Klingberg, Eva, et al.
Publicado: (2012)

Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis
por: Deminger, Anna, et al.
Publicado: (2020)

Physical function and sex differences in radiographic axial spondyloarthritis: a cross-sectional analysis on Bath Ankylosing Spondylitis Functional Index
por: Hallström, Magnus, et al.
Publicado: (2023)

Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes
por: Klingberg, Eva, et al.
Publicado: (2013)

A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis
por: Deminger, Anna, et al.
Publicado: (2018)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study
por: Deminger, Anna, et al.
Publicado: (2017)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study
por: Lindström, Ulf, et al.
Publicado: (2016)

Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study
por: Forsblad-d’Elia, Helena, et al.
Publicado: (2013)

Patterns of comorbidity and disease characteristics among patients with ankylosing spondylitis—a cross-sectional study
por: Ljung, Lotta, et al.
Publicado: (2017)

Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis
por: Södergren, Anna, et al.
Publicado: (2020)

Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
por: Torres, L., et al.
Publicado: (2018)

Increased proportions of inflammatory T cells and their correlations with cytokines and clinical parameters in patients with ankylosing spondylitis from northern Sweden
por: Lejon, Kristina, et al.
Publicado: (2022)

A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis
por: Klingberg, Eva, et al.
Publicado: (2017)

Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex
por: Law, Lucy, et al.
Publicado: (2018)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case–control study based on national registers
por: Lindström, Ulf, et al.
Publicado: (2016)

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2017)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study
por: Bengtsson, Karin, et al.
Publicado: (2019)

The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study
por: Exarchou, Sofia, et al.
Publicado: (2015)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin
por: Klingberg, Eva, et al.
Publicado: (2019)

Occurrence and relative risks for non-vertebral fractures in patients with ankylosing spondylitis compared with the general population: a register-based study from Sweden
por: Bengtsson, Karin, et al.
Publicado: (2023)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Comparison of HLA-B*27 subtypes between Chinese patients with ankylosing spondylitis and non-ankylosing spondylitis carriers
por: Luo, Fangjun, et al.
Publicado: (2019)

Role of HLA-B27 in the pathogenesis of ankylosing spondylitis
por: Chen, Bin, et al.
Publicado: (2017)

Association of Protective HLA-A With HLA-B(∗)27 Positive Ankylosing Spondylitis
por: Nordin, Jessika, et al.
Publicado: (2021)

Factors associated with changes in volumetric bone mineral density and cortical area in men with ankylosing spondylitis: a 5-year prospective study using HRpQCT.
por: Deminger, A., et al.
Publicado: (2021)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_btv5samuiu1ihcafr2k0bllut0